Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Levels After COVID-19 Booster Vaccination
ChiCTR2200062784Phase 4Recruiting
- Sponsor
- Luzhou Center for Disease Control and Prevention
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of turkovac in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Luzhou Center for Disease Control and Prevention. Primary endpoint: SARS-CoV-2 neutralizing antibody. Started Jul 2022; status: recruiting.
02
Drugs
turkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200062784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062784.